LivaNova PLC Stock Price and Value Analysis

LivaNova PLC (NASDAQ:LIVN) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold LivaNova PLC to reach your target.

Target type

LIVN Free Cash Flow Trend

Free Cash Flow trendline for LIVN
Free Cash Flow trendline for LivaNova PLC
CSV

Based on historical returns, we believe that LivaNova PLC can grow its free cash at a rate of about 8%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a decent rate.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the LIVN Numbers

LIVN Price
(LivaNova PLC stock price per share)
$90.73
[?] LIVN Fair Price
(based on intrinsic value)
$21.78
[?] LIVN Safety Price (based on a variable margin of safety) $13.07
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 30% higher than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Devices stocks
[?] Free Cash Flow Jitter 154%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 6,362,366 shares shorted. With 54,821,841 shares available for purchase and an average trading volume over the past 10 trading days of 695,360, it would take at least 9.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2013 1639691 69.3
2014 1639691 41.7
2015 1639691 69.1
2016 1639691 72.7
2017 1639691 70.8
2018 1639691 94.4
2019 1639691 -119
2020 1639691 -113
2021 1639691 71.5
2022 1639691 40.1
2023 1639691 45.6
2024 1639691 149
2025 1639691 211

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 5 fiscal years from 2013 to 2025 with positive net income, operating cash flow totaled $471 million against net income of $240 million, or 1.96 times. Net income was negative in 8 of the 13 years, and those years are left out of the ratio.

In 2025, net income was -$242 million and operating cash flow was $254 million, so no ratio is shown for that year.

In 2025, capital expenditures were $81 million, 31.9% of operating cash flow of $254 million, which leaves an estimated $173 million after capex. Across the 11 years with reported capex, it averaged 29.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2013 46.4 79.1 9.7 1.71
2014 54.9 54.2 15.2 0.99
2015 57.8 79.7 6.7 1.38
2016 -62.8 90.2 38.4 n/a
2017 -25.1 91.3 32.9 n/a
2018 -189 120 37.2 n/a
2019 -158 -91.1 24.7 n/a
2020 -349 -79.4 35 n/a
2021 -136 103 25.5 n/a
2022 -86.2 69.9 26.5 n/a
2023 17.5 74.9 35 4.27
2024 63.2 183 47.1 2.89
2025 -242 254 81 n/a

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 5 fiscal years from 2013 to 2018 with dividend or share repurchase facts, estimated free cash flow totaled $347 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 5 of the 5 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $265 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2018, cash spent repurchasing shares was $50 million, 53.0% of estimated free cash flow of $94.4 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2013 69.3 n/a 33 33 47.6%
2014 41.7 n/a 72.4 72.4 173.4%
2015 69.1 n/a 55 55 79.6%
2016 72.7 n/a 54.5 54.5 75.0%
2018 94.4 n/a 50 50 53.0%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $254 million in 2013 and $1,388 million in 2025, a compound annual growth rate of 15.2% over 12 years.

Revenue rose 10.7% from 2024 to 2025.

Our estimated free cash flow was $211 million in 2025, 15.2% of revenue. In 2013 the estimated margin was 27.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2013 254 69.3 27.3%
2014 282 41.7 14.8%
2015 292 69.1 23.7%
2016 965 72.7 7.5%
2017 1,012 70.8 7.0%
2018 1,107 94.4 8.5%
2019 1,084 -119 -11.0%
2020 934 -113 -12.1%
2021 1,035 71.5 6.9%
2022 1,022 40.1 3.9%
2023 1,154 45.6 4.0%
2024 1,253 149 11.9%
2025 1,388 211 15.2%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $636 million against total liabilities of $1,406 million, or 45.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 54.0% of total assets in 2025, compared with 11.9% in 2014, an increase of 42.0 percentage points.

Stockholders equity was $1,200 million in 2025, compared with $230 million in 2013, a rise of 422.7%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 18.2% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2013 264 103 n/a 230
2014 294 124 35.1 259
2015 316 113 n/a 1,811
2016 2,343 39.8 636 1,707
2017 2,504 93.6 689 1,815
2018 2,550 47.2 1,049 1,500
2019 2,412 61.1 1,034 1,378
2020 2,400 253 1,291 1,109
2021 2,201 208 906 1,295
2022 2,295 214 1,087 1,208
2023 2,430 267 1,152 1,278
2024 2,506 429 1,186 1,320
2025 2,606 636 1,406 1,200

Price Versus Our Estimated Value

At $90.73, the price is above our fair value estimate of $21.78 for LivaNova PLC.

LivaNova PLC reported positive free cash flow in 11 of the 13 fiscal years we have from its current SEC filer.

The latest three years average $135 million in free cash flow against $60.1 million for the earliest three, which is a sharp rise.

Year-to-year variability in free cash flow is volatile, measured at 154%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

No dividend yield is recorded for LivaNova PLC in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 30% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to LivaNova PLC, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
LivaNova PLC (LIVN) 4,998 26.0 - - 317% above
Merit Medical Systems (MMSI) 5,053 31.6 - 1.1% 117% above
Haemonetics Corporation (HAE) 5,472 53.2 - 1.7% 132% above
Integer Holdings Corporation (ITGR) 4,317 42.6 - - 147% above
ICU Medical (ICUI) 4,315 72.2 - 1.4% 29% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.6% 24% below
UFP Technologies (UFPT) 2,253 29.7 - 0.1% 395% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1639691.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 2 of the 13 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: LIVN annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in LIVN

Does LivaNova PLC have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: LIVN

This example shows how we apply the Trendshare checklist to LIVN: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 90.73
    • Market cap: $5.0B
    • EPS: 3.49
  2. Step 2 — Valuation checks

    • P/E: 25.997
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.